18.64
price down icon4.26%   -0.83
after-market Handel nachbörslich: 18.64
loading
Schlusskurs vom Vortag:
$19.47
Offen:
$19.37
24-Stunden-Volumen:
866.45K
Relative Volume:
1.14
Marktkapitalisierung:
$1.52B
Einnahmen:
$305.00K
Nettoeinkommen (Verlust:
$-328.98M
KGV:
-4.8668
EPS:
-3.83
Netto-Cashflow:
$-309.60M
1W Leistung:
+1.08%
1M Leistung:
+10.56%
6M Leistung:
+22.43%
1J Leistung:
+25.61%
1-Tages-Spanne:
Value
$18.12
$19.67
1-Wochen-Bereich:
Value
$18.00
$20.05
52-Wochen-Spanne:
Value
$9.90
$27.20

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name
Firmenname
Viridian Therapeutics Inc
Name
Telefon
617.272.4600
Name
Adresse
221 CRESCENT STREET, WALTHAM
Name
Mitarbeiter
143
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
VRDN's Discussions on Twitter

Vergleichen Sie VRDN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VRDN
Viridian Therapeutics Inc
18.64 1.56B 305.00K -328.98M -309.60M -3.83
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
396.93 102.81B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
453.54 58.59B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
567.22 61.25B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
733.66 43.23B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
318.73 36.53B 3.81B -644.79M -669.77M -6.24

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-08-25 Fortgesetzt Jefferies Buy
2024-12-19 Herabstufung Wells Fargo Overweight → Equal Weight
2024-11-25 Eingeleitet TD Cowen Buy
2024-09-11 Bestätigt Needham Buy
2024-06-11 Eingeleitet Wolfe Research Outperform
2024-06-06 Eingeleitet Goldman Buy
2024-05-09 Herabstufung B. Riley Securities Buy → Neutral
2024-05-09 Herabstufung Ladenburg Thalmann Buy → Neutral
2023-06-14 Eingeleitet BTIG Research Buy
2023-06-14 Fortgesetzt Credit Suisse Outperform
2023-05-30 Eingeleitet RBC Capital Mkts Outperform
2023-04-17 Eingeleitet Wells Fargo Overweight
2023-03-30 Eingeleitet Stifel Buy
2022-12-19 Eingeleitet Cowen Outperform
2022-12-19 Eingeleitet Needham Buy
2022-12-16 Eingeleitet Credit Suisse Outperform
2022-12-01 Eingeleitet H.C. Wainwright Buy
2022-06-23 Eingeleitet B. Riley Securities Buy
2021-11-18 Eingeleitet SVB Leerink Outperform
2021-10-12 Eingeleitet Evercore ISI Outperform
2021-01-25 Eingeleitet Ladenburg Thalmann Buy
Alle ansehen

Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten

pulisher
Sep 03, 2025

Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener

Sep 03, 2025
pulisher
Sep 03, 2025

Can Viridian Therapeutics Inc. lead its sector in growthTrade Performance Summary & AI Driven Price Forecasts - khodrobank.com

Sep 03, 2025
pulisher
Sep 03, 2025

Can Viridian Therapeutics Inc. reach all time highs this yearWeekly Trading Summary & High Accuracy Swing Entry Alerts - khodrobank.com

Sep 03, 2025
pulisher
Sep 03, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Sep 03, 2025
pulisher
Sep 03, 2025

Measuring Viridian Therapeutics Inc.’s beta against major indicesM&A Rumor & Daily Stock Trend Reports - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Published on: 2025-09-03 09:36:11 - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Pattern recognition hints at Viridian Therapeutics Inc. upsideQuarterly Portfolio Summary & Community Consensus Trade Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Candlestick signals on Viridian Therapeutics Inc. stock today2025 Earnings Surprises & Risk Adjusted Buy/Sell Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Is a relief rally coming for Viridian Therapeutics Inc. holdersWeekly Profit Analysis & AI Enhanced Trading Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Viridian Therapeutics Inc. stock momentum explainedJuly 2025 Price Swings & Accurate Buy Signal Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Will Viridian Therapeutics Inc. bounce back from current supportShort Setup & Long Hold Capital Preservation Plans - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Will breakout in Viridian Therapeutics Inc. lead to full recoveryMarket Risk Summary & Weekly Momentum Stock Picks - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Will Viridian Therapeutics Inc. rebound enough to break evenJuly 2025 Price Swings & Capital Protection Trading Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

How to use Fibonacci retracement on Viridian Therapeutics Inc.Weekly Investment Recap & Smart Investment Allocation Tips - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Technical analysis overview for Viridian Therapeutics Inc. stockJuly 2025 Sector Moves & Short-Term Swing Trade Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Is Viridian Therapeutics Inc. trading at a discountJuly 2025 Weekly Recap & Daily Entry Point Alerts - khodrobank.com

Sep 03, 2025
pulisher
Sep 02, 2025

Leading vs lagging indicators on Viridian Therapeutics Inc. performanceQuarterly Investment Review & Weekly High Potential Alerts - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Does Viridian Therapeutics Inc. have a competitive edgeJuly 2025 Weekly Recap & Community Consensus Trade Alerts - khodrobank.com

Sep 02, 2025
pulisher
Sep 02, 2025

Will Viridian Therapeutics Inc. see short term momentum2025 Buyback Activity & Long Hold Capital Preservation Tips - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Published on: 2025-09-02 12:18:28 - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Is Viridian Therapeutics Inc. a turnaround storyJuly 2025 Snapshot & Verified Entry Point Signals - khodrobank.com

Sep 02, 2025
pulisher
Sep 02, 2025

Viridian Therapeutics Inc. stock trend outlook and recovery pathEarnings Overview Report & Real-Time Buy Zone Alerts - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Is Viridian Therapeutics Inc. a good ESG investmentJuly 2025 Drop Watch & Safe Investment Capital Preservation Plans - khodrobank.com

Sep 02, 2025
pulisher
Sep 01, 2025

Published on: 2025-09-01 22:08:54 - Newser

Sep 01, 2025
pulisher
Sep 01, 2025

Is Viridian Therapeutics Inc. stock a value trap2025 Risk Factors & Verified Momentum Watchlists - khodrobank.com

Sep 01, 2025
pulisher
Sep 01, 2025

Price Consolidation Hints at Upcoming Move in Viridian Therapeutics Inc.2025 Year in Review & Safe Capital Growth Plans - sundaytimes.kr

Sep 01, 2025
pulisher
Aug 31, 2025

Applying big data sentiment scoring on Viridian Therapeutics Inc.2025 Winners & Losers & Safe Entry Momentum Tips - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Will Viridian Therapeutics Inc. stock recover after recent dropJuly 2025 Sentiment & Stock Market Timing Techniques - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Combining price and volume data for Viridian Therapeutics Inc.2025 Price Action Summary & High Return Trade Guides - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Published on: 2025-08-31 12:51:18 - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Identifying reversal signals in Viridian Therapeutics Inc.July 2025 Closing Moves & Momentum Based Trading Signals - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Detecting price anomalies in Viridian Therapeutics Inc. with AIPortfolio Profit Report & Fast Gain Swing Alerts - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Analyzing Viridian Therapeutics Inc. with multi timeframe charts2025 Big Picture & Precise Entry and Exit Recommendations - Newser

Aug 31, 2025
pulisher
Aug 30, 2025

What momentum shifts mean for Viridian Therapeutics Inc.2025 Bull vs Bear & High Return Trade Opportunity Guides - Newser

Aug 30, 2025

Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Viridian Therapeutics Inc-Aktie (VRDN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Fairmount Funds Management LLC
Director
Jun 09 '25
Option Exercise
7.80
1,600
12,480
3,447,413
Beetham Thomas W.
Chief Operating Officer
Sep 27 '24
Buy
23.41
5,000
117,050
6,000
Mahoney Stephen F.
President and CEO
Sep 27 '24
Buy
23.33
21,400
499,262
21,400
Fairmount Funds Management LLC
Director
Sep 13 '24
Buy
18.75
1,600,000
30,000,000
3,445,813
$85.44
price down icon 1.75%
$27.38
price up icon 1.11%
$23.80
price up icon 1.19%
$103.50
price up icon 3.07%
$142.53
price down icon 0.68%
biotechnology ONC
$318.73
price down icon 5.21%
Kapitalisierung:     |  Volumen (24h):